Backup – Pipeline – Graph Change

Pipeline

Autifony’s pipeline includes clinical stage programmes for Schizophrenia, age related hearing loss, Fragile X and earlier stage programmes focused on ALS and Alzheimer’s Disease.

Therapeutic area
Compound
(Target)
Indication
Preclinical
Phase 1
Phase 2
Psychiatry
AUT00206
(Kv3.1/3.2)
Schizophrenia
Neurology
AUT00206
(Kv3.1/3.2)
Fragile X
Kv3.1
Hearing disorders
Undisclosed target
Alzheimer’s Disease

Related News

18Dec

Autifony Therapeutics and Boehringer Ingelheim collaborate on a novel therapeutic approach to a range of CNS disorders

0 Comments
Collaboration with funding of development activities gives Boehringer Ingelheim exclusive option to purchase certain Autifony assets to treat serious CNS... Read More →
10Jul

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
18May

Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
10Jan

Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

0 Comments
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous... Read More →
09Aug

Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss

0 Comments
Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of... Read More →
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image